Format

Send to

Choose Destination
Cell Stem Cell. 2015 Jul 2;17(1):11-22. doi: 10.1016/j.stem.2015.06.007.

Stem Cell Therapies in Clinical Trials: Progress and Challenges.

Author information

1
Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia. Electronic address: alan.trounson@hudson.org.au.
2
Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia.

Abstract

Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising from autologous or allogeneic transplants. Many cells administered show transient presence for a few days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some with early benefits to patients.

PMID:
26140604
DOI:
10.1016/j.stem.2015.06.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center